SCIENCE NEWS Molecular Discovery Suggests New Strategy to Fight Cancer Drug Resistance Scientists have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer. [Press release from the Dana-Farber Cancer Institute discussing online prepublication in Nature Chemical Biology] Clinical Trials Favorable for Novel Breast Cancer Detection Device A novel imaging device is showing favorable results in an expanded clinical trial and could significantly reduce physicians’ reliance on breast biopsies. [Press release from the University of Connecticut discussing online prepublication in Radiology] Gene Mutation Increases Thromboembolism Risk in Women Taking Tamoxifen Women taking tamoxifen for early-stage breast cancer who developed blood clots were more likely to carry a gene mutation for clotting than women taking tamoxifen who did not develop blood clots. [Press release from ScienceDaily discussing online prepublication in the Journal of the National Cancer Institute] Breast Cancer Prophylaxis Although the recent FDA approval of Dendreon Corp.’s Provenge therapeutic vaccine for prostate cancer finally has cemented immunotherapy’s place in the cancer armamentarium, the development of prophylactic cancer vaccines has lagged far behind. [SciBX Press Release]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH A Mouse Knockout Library for Secreted and Transmembrane Proteins Large collections of knockout organisms facilitate the elucidation of gene functions. Here, researchers used retroviral insertion or homologous recombination to disrupt 472 genes encoding secreted and membrane proteins in mice, providing a resource for studying a large fraction of this important class of drug target. [Nat Biotechnol] The MCL-1 BH3 Helix is an Exclusive MCL-1 Inhibitor and Apoptosis Sensitizer By screening a library of stabilized alpha-helix of BCL-2 domains, researchers determined that the MCL-1 BH3 helix is itself a potent and exclusive MCL-1 inhibitor. [Nat Chem Biol] Interference with Sin3 Function Induces Epigenetic Reprogramming and Differentiation in Breast Cancer Cells Here, researchers show that in both human and mouse breast cancer cells, the targeted disruption of Sin3 function by introduction of a Sin3 interaction domain (SID) decoy that interferes with paired amphipathic alpha-helices binding to SID-containing partner proteins reverted the silencing of genes involved in cell growth and differentiation. [Proc Natl Acad Sci U S A] Notch1-Induced Mammary Tumor Development is Cyclin D1-Dependent and Correlates with Expansion of Pre-Malignant Multipotent Duct-Limited Progenitors In young transgenic mice, expressing intracellular activated Notch1 [N1(IC)] in mammary cells, researchers found that CD24(+) CD29(high) progenitor cells had enhanced survival, and were expanded through a cyclin D1-dependent pathway. [Oncogene] Deletion of p53 in Human Mammary Epithelial Cells Causes Chromosomal Instability and Altered Therapeutic Response To evaluate the biological and clinical relevance of p53 loss, human somatic cell gene targeting was used to delete the TP53 gene in the non-tumorigenic epithelial cell line, MCF-10A. [Oncogene] Molecular Subtypes of Breast Cancer are Associated with Characteristic DNA Methylation Patterns Researchers analysed methylation status of 807 cancer-related genes in 189 fresh frozen primary breast tumours and four normal breast tissue samples using an array-based methylation assay. [Breast Cancer Res] Cooperative Signaling Between Wnt1 and Integrin-Linked Kinase Induces Accelerated Breast Tumor Development In order to investigate the potential interaction between Wnt and integrin-linked kinase (ILK) proteins during mammary tumor formation and progression, researchers have established a transgenic mouse model which expresses both Wnt and ILK in mammary epithelial cells. [Breast Cancer Res] Placental Growth Factor (PlGF) Enhances Breast Cancer Cell Motility by Mobilising ERK1/2 Phosphorylation and Cytoskeletal Rearrangement The purpose of this study was to determine the intracellular effects of PlGF and the inhibiting peptide, BP-1. [Br J Cancer] CLINICAL RESEARCH Use of Bisphosphonates and Risk of Postmenopausal Breast Cancer The use of bisphosphonates for longer than 1 year was associated with a 28% relative reduction in the risk of postmenopausal breast cancer. Tumors developing under bisphosphonates treatment tended to have a favorable prognostic factors profile. [J Clin Oncol] Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer Among women taking adjuvant tamoxifen for early-stage breast cancer, those who had a thromboembolic event (TE) were nearly five times more likely to carry a Factor V Leiden mutation than those who did not have a TE. [J Natl Cancer Inst]
|
|
POLICY NEWS Hospital Clínic de Barcelona Obtained the First Accreditation for Cell Therapy Research The certification, awarded for the first time in Catalonia, allows the Hospital Clínic de Barcelona to produce drugs in gene therapy, cell therapy and tissue engineering. [Spanish Medicines Agency, Spain] New Videos Reveal How NIH Identifies the Most Promising Research Applications The National Institutes of Health’s Center for Scientific Review released a new video to show new applicants and others how NIH assesses over 80,000 grant applications each year to help find those with the most merit. [National Institutes of Health, United States] NIH and Wellcome Trust Announce Partnership to Support Genomic, Population-Based Studies in Africa The National Institutes of Health (NIH) and the Wellcome Trust announced a partnership with African researchers to conduct genetic and environmental studies in Africa of common, non-communicable disorders, such as heart disease and cancer, as well as communicable diseases, such as malaria. [National Institutes of Health, United States] Publication of New Enforcement Strategy A new enforcement strategy has been published by the Inspection, Enforcement and Standards Division. [Medicines and Healthcare Products Regulatory Agency, United Kingdom] Drugs Designated as Orphan Drugs [Therapeutic Goods Administration, Australia] Therapeutic Goods Committee (TGC) (Updated) [Therapeutic Goods Administration, Australia]
|
|
EVENTS The 21st Meeting of the European Association for Cancer Research (EACR) June 26-29, 2010 Oslo, Norway United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference July 12-14, 2010 Nottingham, United Kingdom 2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2) August 2-4, 2010 Singapore City, Singapore Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States 15th Congress of the European Society of Surgical Oncology (ESSO) September 15-17, 2010 Bordeaux, France 2010 World Cancer Congress August 18-21, 2010 Shenzhen, China 35th European Society for Medical Oncology (ESMO) Congress October 8-12, 2010 Milan, Italy International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy October 18-19, 2010 West Lafayette, United States 6th National Cancer Research Institute (NCRI) Conference November 7-10, 2010 Liverpool, United Kingdom JOB OPPORTUNITIES Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies) Business Development Manager Europe – Cell Therapy Products (Pall Corporation) Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News. Visit here to post your career opportunities. Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
Have we missed an important article or publication in Mammary Cell News? Click here to submit! |
| |
|